CBD has become one of the most common ingredients in products marketed for pain, soreness and recovery.
You can now find it in balms, creams, oils, roll-ons, gummies and dozens of other formats. But widespread use does not automatically mean the science is settled.
Current human research does not support CBD as a proven, universal treatment for pain. The evidence is mixed and depends heavily on the type of pain, whether CBD is taken orally or applied topically, the formulation used, and the specific study.
Some small trials of topical CBD have reported improvements in particular pain conditions. Other randomized studies have found little or no difference from placebo.
So rather than asking simply, “Does CBD work for pain?” a better question is:
What does the research actually show?
What Does the Research Say About CBD for Pain Relief?
CBD pain research includes laboratory studies, animal research, observational studies and human clinical trials.
That creates an important distinction.
A biological mechanism that looks promising in laboratory research is not the same as demonstrating meaningful pain relief in people.
A recent systematic review of CBD and pain research evaluated both clinical and preclinical evidence. The authors found promising signals across several models and conditions, while also noting that the human clinical evidence remains limited and that additional well-designed studies are needed.
A broader picture comes from the U.S. Agency for Healthcare Research and Quality.
Its Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain continuously evaluates randomized and observational research.
In its 2024 update, purified oral CBD alone was not associated with meaningful improvements in chronic pain or physical function compared with placebo across the included trials. Evidence for topical CBD and several other cannabinoid formats remained insufficient for firm conclusions.
The National Center for Complementary and Integrative Health overview of cannabis and cannabinoids reaches a similarly cautious conclusion. Some cannabis and cannabinoid preparations may offer modest benefit for certain chronic pain conditions, but much of that research involves THC-containing products rather than CBD alone.
That distinction matters.
A study using an oral THC/CBD product cannot automatically tell us how a CBD-only topical balm will perform.
What Have Human Studies Found About Topical CBD?
For PHASIS, the topical studies are particularly relevant because Max Relief and Relief are applied directly to the skin.
There are now several human trials of topical CBD, but the findings are not uniform.
Thumb arthritis
A small randomized, double-blind crossover trial studied adults with symptomatic thumb basal joint arthritis.
Participants used topical CBD or a control formulation for two weeks before crossing over to the alternative treatment.
The researchers reported improvements in patient-reported pain and disability during the CBD treatment period.
You can review the randomized controlled trial of topical CBD for thumb arthritis directly on PubMed.
It is an encouraging result, but there are important limitations.
The trial involved only 18 participants, was short in duration and evaluated one particular CBD formulation in one particular condition.
It should not be interpreted as proof that every topical CBD product produces the same outcome.
Peripheral neuropathy
Another randomized study evaluated topical CBD in 29 people experiencing symptomatic peripheral neuropathy.
The CBD group reported improvements in several symptoms, including intense and sharp pain sensations, compared with placebo.
The full topical CBD peripheral neuropathy study is available through PubMed.
Again, the result is interesting, but the study population was small.
Chemotherapy-induced neuropathy
Other trials have produced less positive results.
A randomized pilot study involving people with established chemotherapy-induced peripheral neuropathy compared topical CBD with placebo.
Researchers did not identify a clear treatment effect with the CBD product that was studied.
The randomized topical CBD chemotherapy-induced neuropathy trial provides a useful example of why results from one pain condition cannot automatically be applied to another.
Exercise-related muscle soreness
CBD topicals are also frequently marketed toward athletes and people recovering from training.
A randomized, double-blind, placebo-controlled pilot study examined topical CBD after a muscle-damaging exercise protocol.
The researchers did not find significant improvements in soreness, pain threshold, strength or performance with the CBD cream compared with placebo.
The topical CBD muscle soreness and performance study can be reviewed directly on PubMed.
Taken together, these studies demonstrate why a simple “CBD works” or “CBD does not work” conclusion is not very useful.
Human topical CBD research is still relatively small, condition-specific and mixed.
Some trials have reported meaningful improvements.
Others have not.
Why Do CBD Studies Produce Different Results?
One reason the CBD conversation becomes confusing is that very different products and conditions are often grouped together under the same term.
Different kinds of pain
“Pain” is not a single biological condition.
Neuropathic pain differs from arthritis-related pain.
Arthritis-related pain differs from post-exercise soreness.
Post-surgical pain, acute injury and long-term musculoskeletal discomfort create different research questions again.
A result in one condition cannot automatically be assumed to apply to another.
Different delivery methods
CBD can be:
-
swallowed
-
taken sublingually
-
applied topically
-
formulated for transdermal delivery
Those routes produce different patterns of exposure.
The AHRQ evidence review, for example, found that purified oral CBD did not meaningfully improve chronic pain outcomes in the trials it evaluated, while evidence around topical CBD remained too limited for broad conclusions.
That is why oral CBD evidence and topical CBD evidence should not be treated as interchangeable.
Different formulations
The phrase “CBD cream” does not describe one standardized formula.
Products may contain:
-
CBD isolate
-
full-spectrum hemp extract
-
different CBD concentrations
-
different carrier bases
-
different application amounts
-
additional active or botanical ingredients
Those differences matter when interpreting research.
A trial involving a CBD isolate cream does not automatically predict the experience of using a full-spectrum topical with other ingredients.
Small sample sizes
Many human topical CBD trials include only a few dozen participants.
Small studies can identify interesting signals and help guide further research, but they are not the same as large, replicated clinical trials.
At PHASIS, we believe positive research should be discussed confidently when it is accurately represented, but a single study should never be turned into a universal product promise.
How Might CBD Affect Pain-Related Pathways?
CBD biology is more complex than the idea that it simply “blocks pain.”
Researchers have studied CBD's interaction with several signaling systems involved in sensory processing and inflammatory responses.
The 2024 systematic review of CBD in pain research discusses potential involvement of pathways including TRPV1 and serotonin-related signaling, along with interactions involving the endocannabinoid system.
These mechanisms help explain why CBD remains an active area of research.
But mechanism should not be confused with clinical proof.
Showing that CBD interacts with a pathway associated with pain processing does not prove that every finished CBD topical will produce meaningful pain relief in people.
That distinction is important because supplement and wellness marketing can sometimes turn a plausible biological mechanism into a claim that goes further than the human evidence supports.
Our view at PHASIS is straightforward:
Use mechanisms to inform formulation and research, not to create guarantees.
What Should You Look for in a CBD Topical?
Uncertainty in the research does not mean product quality is irrelevant.
In many ways, it makes transparency more important.
Consumers should be able to determine:
-
what form of hemp extract is used
-
the CBD concentration
-
what other ingredients are present
-
whether the formula has been third-party tested
-
whether the label clearly discloses what is in the product
-
what kind of topical experience the formula is intended to provide
At PHASIS, we do not believe a topical should be judged only by the largest CBD number printed on the label.
The complete formula matters.
CBD concentration is important, but so is what accompanies it.
This is especially relevant when comparing products that may all say “CBD balm” on the front while containing very different formulas.
Why PHASIS Uses Full-Spectrum Hemp Extract
PHASIS uses full-spectrum hemp extract in its topical products rather than CBD isolate.
Full-spectrum hemp preserves a broader naturally occurring plant profile, including CBD alongside other cannabinoids, terpenes and hemp compounds.
CBD isolate, by comparison, is purified CBD.
That is a real formulation difference.
It does not require claiming that full spectrum has been clinically proven to outperform isolate for every condition.
PHASIS chose full-spectrum hemp because retaining the broader plant profile fits the way we design our topical formulas.
Our products also look beyond CBD alone.
Max Relief combines full-spectrum hemp extract at a stated concentration of 20 mg/mL with a multi-ingredient topical formula including lidocaine HCl, menthol, capsaicin, arnica and turmeric.
For people looking for a gentler everyday topical, Relief Balm combines full-spectrum hemp extract with a botanical-focused balm formula designed for regular massage and topical use.
Both reflect the same PHASIS principle:
Evaluate the complete formula, not one number in isolation.
Third-party testing and transparent labeling are also part of the broader PHASIS standards and formulation philosophy.
What Should You Know Before Using CBD for Pain?
CBD products are widely available, but availability should not be confused with FDA approval for treating pain.
The FDA's consumer guidance on CBD products states that the agency has approved only one prescription drug containing CBD, for specific seizure disorders. Over-the-counter CBD products are not FDA-approved medicines for treating pain.
The FDA also notes that CBD can have safety considerations, including potential drug interactions and liver-related effects in some circumstances.
For topical products, practical considerations include:
-
follow the product's directions
-
review the full ingredient list
-
avoid damaged or irritated skin unless the product specifically directs otherwise
-
stop use if significant irritation develops
-
consider a small patch test if you have particularly sensitive skin
-
speak with an appropriate healthcare professional when pain is severe, persistent, unexplained or associated with a diagnosed medical condition
Pregnancy and breastfeeding require additional caution.
The FDA specifically advises against CBD use during pregnancy or while breastfeeding. The agency explains its position in its guidance on cannabis and CBD during pregnancy and breastfeeding.
People subject to drug testing should also use caution with full-spectrum hemp products because they may contain trace amounts of THC.
A consumer CBD product should never be presented as guaranteeing a particular drug-test outcome.
Most importantly, CBD should not replace appropriate medical assessment when ongoing pain may require diagnosis or established treatment.
The Bottom Line
CBD and pain is an active area of research, but the evidence is more nuanced than many marketing claims suggest.
Small human studies of topical CBD have reported positive results in conditions such as thumb arthritis and peripheral neuropathy.
Other randomized trials, including studies involving chemotherapy-related neuropathy and exercise-induced muscle soreness, have not shown clear benefits over placebo.
Large evidence reviews still conclude that the overall topical CBD evidence is limited.
That does not mean formulation is unimportant.
It means consumers should look closely at what they are actually buying.
At PHASIS, that means considering:
-
the type of hemp extract
-
CBD concentration
-
the complete active formula
-
ingredient transparency
-
third-party testing
-
the intended topical experience
The science should guide the conversation without being stretched beyond what it actually demonstrates.
Frequently Asked Questions
Does CBD actually help with pain?
Human research is mixed. Some small topical CBD trials have reported improvements in specific conditions, while other randomized studies have found no clear benefit over placebo. Current evidence does not establish CBD as a universal pain treatment.
What does the research say about topical CBD?
Topical CBD has been studied in conditions including arthritis, peripheral neuropathy, chemotherapy-related neuropathy and exercise-induced muscle soreness. Results vary considerably between studies and formulations.
Is topical CBD better than oral CBD for pain?
Current research does not establish that one route is universally better. Oral and topical CBD are different delivery methods and have been studied using different doses, formulations and patient groups.
Is full-spectrum CBD different from CBD isolate?
Yes. CBD isolate is purified CBD, while full-spectrum hemp extract retains CBD along with a broader profile of naturally occurring cannabinoids, terpenes and other hemp compounds.
Is CBD FDA-approved for pain?
No. The FDA has approved one prescription CBD drug for certain seizure disorders, but over-the-counter CBD products are not FDA-approved drugs for treating pain.
